Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michelle R Mahoney

Showing results (1-10 of 47) with videos related to

Pageof 5
Sort By:
Lancet (London, England)|January 24, 2007
Adverse-event rates: journals versus databasesMichelle R Mahoney, Daniel J Sargent
American Journal of Clinical Oncology|June 1, 2004
Topotecan in patients with advanced neuroendocrine tumors: a phase II study with significant hematologic toxicityStephen M Ansell, Michelle R Mahoney, Erin M Green, et al.
Cancer Investigation|August 29, 2002
Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomasJohn H Edmonson, Randolph S Marks, Jan C Buckner, et al.
Journal of Geriatric Oncology|September 18, 2017
Challenges of conducting a prospective clinical trial for older patients: Lessons learned from NCCTG N0949 (alliance)Nadine J McCleary, Joleen Hubbard, Michelle R Mahoney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 20, 2005
Dealing with a deluge of data: an assessment of adverse event data on North Central Cancer Treatment Group trialsMichelle R Mahoney, Daniel J Sargent, Michael J O'Connell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 28, 2002
Early detection of toxicity and adjustment of ongoing clinical trials: the history and performance of the North Central Cancer Treatment Group's real-time toxicity monitoring programRichard M Goldberg, Daniel J Sargent, Roscoe F Morton, et al.
Cancers|November 7, 2020
Adverse Event Burden Score-A Versatile Summary Measure for Cancer Clinical TrialsJennifer G Le-Rademacher, Shauna Hillman, Elizabeth Storrick, et al.
Cancer|February 3, 2011
A phase 2 study of temsirolimus (CCI-779) in patients with soft tissue sarcomas: a study of the Mayo phase 2 consortium (P2C)Scott Okuno, Howard Bailey, Michelle R Mahoney, et al.
Cancer|September 29, 2011
Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancerPhilip A Philip, Michelle R Mahoney, Kyle D Holen, et al.
Cancer|October 24, 2006
Phase II study of daily oral perifosine in patients with advanced soft tissue sarcomaHoward H Bailey, Michelle R Mahoney, David S Ettinger, et al.
Pageof 5

Showing results (1-10 of 47) with videos related to

Sort By:
Pageof 5
Lancet (London, England)|January 24, 2007
Adverse-event rates: journals versus databasesMichelle R Mahoney, Daniel J Sargent
American Journal of Clinical Oncology|June 1, 2004
Topotecan in patients with advanced neuroendocrine tumors: a phase II study with significant hematologic toxicityStephen M Ansell, Michelle R Mahoney, Erin M Green, et al.
Cancer Investigation|August 29, 2002
Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomasJohn H Edmonson, Randolph S Marks, Jan C Buckner, et al.
Journal of Geriatric Oncology|September 18, 2017
Challenges of conducting a prospective clinical trial for older patients: Lessons learned from NCCTG N0949 (alliance)Nadine J McCleary, Joleen Hubbard, Michelle R Mahoney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 20, 2005
Dealing with a deluge of data: an assessment of adverse event data on North Central Cancer Treatment Group trialsMichelle R Mahoney, Daniel J Sargent, Michael J O'Connell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 28, 2002
Early detection of toxicity and adjustment of ongoing clinical trials: the history and performance of the North Central Cancer Treatment Group's real-time toxicity monitoring programRichard M Goldberg, Daniel J Sargent, Roscoe F Morton, et al.
Cancers|November 7, 2020
Adverse Event Burden Score-A Versatile Summary Measure for Cancer Clinical TrialsJennifer G Le-Rademacher, Shauna Hillman, Elizabeth Storrick, et al.
Cancer|February 3, 2011
A phase 2 study of temsirolimus (CCI-779) in patients with soft tissue sarcomas: a study of the Mayo phase 2 consortium (P2C)Scott Okuno, Howard Bailey, Michelle R Mahoney, et al.
Cancer|September 29, 2011
Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancerPhilip A Philip, Michelle R Mahoney, Kyle D Holen, et al.
Cancer|October 24, 2006
Phase II study of daily oral perifosine in patients with advanced soft tissue sarcomaHoward H Bailey, Michelle R Mahoney, David S Ettinger, et al.
Pageof 5